JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 14, 2006; DOI: 10.1124/jpet.106.110510


0022-3565/06/3193-1172-1181$20.00
JPET 319:1172-1181, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.110510v1
319/3/1172    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shankaran, M.
Right arrow Articles by Hellerstein, M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shankaran, M.
Right arrow Articles by Hellerstein, M. K.

NEUROPHARMACOLOGY

Discovery of Novel Hippocampal Neurogenic Agents by Using an in Vivo Stable Isotope Labeling Technique

Mahalakshmi Shankaran, Chelsea King, Jean Lee, Robert Busch, Mary Wolff, and Marc K. Hellerstein

KineMed, Inc., Emeryville, California (M.S., C.K., J.L., R.B., M.W.); and Department of Nutritional Sciences and Toxicology, University of California Berkeley, Berkeley, California (M.K.H.)

Neurogenesis occurs in discrete regions of adult mammalian brain, including the subgranular zone of the hippocampus. Hippocampal neurogenesis is enhanced by different classes of antidepressants, but screening for neurogenic actions of novel antidepressants has been inefficient because of limitations of 5-bromo-2'-deoxyuridine labeling techniques. We describe an efficient in vivo method for measuring hippocampal neurogenesis involving incorporation of the stable isotope, 2H, into genomic DNA during labeling with 2H2O (heavy water). Male rodents received 8 to 10% 2H2O in drinking water; DNA was isolated from hippocampal progenitor cells or neurons. Label incorporation into progenitor cells of Swiss-Webster mice revealed subpopulation kinetics: 16% divided with t1/2 of 2.7 weeks; the remainder did not divide over 1 year. Progenitor cell proliferation rates in mice were strain-dependent. Chronic antidepressant treatment for 3 weeks, with 2H2O administered during the final week, increased progenitor cell proliferation across all the strains tested. Fluoxetine treatment increased 2H incorporation into DNA of gradient-enriched neurons or flow-sorted neuronal nuclei 4 weeks after 2H2O labeling, representing the survival and differentiation of newly divided cells into neurons. By screening 11 approved drugs for effects on progenitor cell proliferation, we detected previously unrecognized, dose-dependent enhancement of hippocampal progenitor cell proliferation by two statins and the anticonvulsant topiramate. We also confirmed stimulatory activity of other anticonvulsants and showed inhibition of progenitor cell proliferation by isotretinoin and prednisolone. In conclusion, stable isotope labeling is an efficient, high-throughput in vivo method for measuring hippocampal progenitor cell proliferation that can be used to screen for novel neurogenic drugs.


Received July 11, 2006; accepted September 12, 2006.

Address correspondence to: Dr. Mahalakshmi Shankaran, KineMed, Inc., 5980 Horton Street, Suite 400, Emeryville, CA 94608. E-mail: mshankaran{at}kinemed.com




This article has been cited by other articles:


Home page
Genome ResHome page
M. P. Keller, Y. Choi, P. Wang, D. Belt Davis, M. E. Rabaglia, A. T. Oler, D. S. Stapleton, C. Argmann, K. L. Schueler, S. Edwards, et al.
A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility
Genome Res., May 1, 2008; 18(5): 706 - 716.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. K. Hellerstein
Exploiting Complexity and the Robustness of Network Architecture for Drug Discovery
J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 1 - 9.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.